Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10190954" target="_blank" >RIV/00216208:11110/13:10190954 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68407700:21230/13:00202267 RIV/00064165:_____/13:10190954

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00702-012-0853-4" target="_blank" >http://dx.doi.org/10.1007/s00702-012-0853-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00702-012-0853-4" target="_blank" >10.1007/s00702-012-0853-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy

Popis výsledku v původním jazyce

Despite the initial reports showing beneficial effects of dopaminergic treatment on speech in Parkinson's disease (PD), more recent studies based upon valid measurements have not approved any improvement of speech performance under pharmacotherapy. The aim of this study was to analyze the effect of treatment initiation on the progression of speech impairment in PD, using novel evaluation criteria. Nineteen de novo patients with PD were tested and retested within 2 years after the introduction of antiparkinsonian therapy. As controls, 19 age-matched individuals were recorded. Speech examination included sustained phonation, fast syllable repetition, reading text, and monolog. Quantitative acoustic analyses of the key aspects of speech based on Gaussiankernel distribution, statistical decision-making theory, and healthy speech observation were used to assess the improvement or deterioration of speech. A trend for speech performances to improve was demonstrated after treatment mainly in

Název v anglickém jazyce

Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy

Popis výsledku anglicky

Despite the initial reports showing beneficial effects of dopaminergic treatment on speech in Parkinson's disease (PD), more recent studies based upon valid measurements have not approved any improvement of speech performance under pharmacotherapy. The aim of this study was to analyze the effect of treatment initiation on the progression of speech impairment in PD, using novel evaluation criteria. Nineteen de novo patients with PD were tested and retested within 2 years after the introduction of antiparkinsonian therapy. As controls, 19 age-matched individuals were recorded. Speech examination included sustained phonation, fast syllable repetition, reading text, and monolog. Quantitative acoustic analyses of the key aspects of speech based on Gaussiankernel distribution, statistical decision-making theory, and healthy speech observation were used to assess the improvement or deterioration of speech. A trend for speech performances to improve was demonstrated after treatment mainly in

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neural Transmission

ISSN

0300-9564

e-ISSN

—

Svazek periodika

120

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

AT - Rakouská republika

Počet stran výsledku

11

Strana od-do

319-329

Kód UT WoS článku

000314043000009

EID výsledku v databázi Scopus

—